Literature DB >> 22133841

Voltage-gated calcium channels and Parkinson's disease.

Michael J Hurley1, David T Dexter.   

Abstract

A complex interaction of environmental, genetic and epigenetic factors combine with ageing to cause the most prevalent of movement disorders Parkinson's disease. Current pharmacological treatments only tackle the symptoms and do not stop progression of the disease or reverse the neurodegenerative process. While some incidences of Parkinson's disease arise through heritable genetic defects, the cause of the majority of cases remains unknown. Likewise, why some neuronal populations are more susceptible to neurodegeneration than others is not clear, but as the molecular pathways responsible for the process of cell death are unravelled, it is increasingly apparent that disrupted cellular energy metabolism plays a central role. Precise control of cellular calcium concentrations is crucial for maintenance of energy homeostasis. Recently, differential cellular expression of neuronal voltage-gated calcium channel (Ca(V)) isoforms has been implicated in the susceptibility of vulnerable neurons to neurodegeneration in Parkinson's disease. Ca(V) channels are also involved in the synaptic plasticity response to the denervation that occurs in Parkinson's disease and following chronic treatment with anti-parkinsonian drugs. This review will examine the putative role neuronal Ca(V) channels have in the pathogenesis and treatment of Parkinson's disease.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22133841     DOI: 10.1016/j.pharmthera.2011.11.006

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  10 in total

1.  Lower Affinity of Isradipine for L-Type Ca2+ Channels during Substantia Nigra Dopamine Neuron-Like Activity: Implications for Neuroprotection in Parkinson's Disease.

Authors:  Nadine J Ortner; Gabriella Bock; Antonios Dougalis; Maria Kharitonova; Johanna Duda; Simon Hess; Petronel Tuluc; Thomas Pomberger; Nadia Stefanova; Florian Pitterl; Thomas Ciossek; Herbert Oberacher; Henning J Draheim; Peter Kloppenburg; Birgit Liss; Jörg Striessnig
Journal:  J Neurosci       Date:  2017-06-07       Impact factor: 6.167

Review 2.  Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson's Disease: Therapeutic Rationale and Current Status.

Authors:  Tara Swart; Michael J Hurley
Journal:  CNS Drugs       Date:  2016-12       Impact factor: 5.749

Review 3.  Altered neural cell junctions and ion-channels leading to disrupted neuron communication in Parkinson's disease.

Authors:  Saptamita Paul Choudhury; Sarika Bano; Srijon Sen; Kapil Suchal; Saroj Kumar; Fredrik Nikolajeff; Sanjay Kumar Dey; Vaibhav Sharma
Journal:  NPJ Parkinsons Dis       Date:  2022-06-01

Review 4.  The role of Ca2+ signaling in Parkinson's disease.

Authors:  Sofia V Zaichick; Kaitlyn M McGrath; Gabriela Caraveo
Journal:  Dis Model Mech       Date:  2017-05-01       Impact factor: 5.758

Review 5.  Can Interactions Between α-Synuclein, Dopamine and Calcium Explain Selective Neurodegeneration in Parkinson's Disease?

Authors:  Michael R Post; Ori J Lieberman; Eugene V Mosharov
Journal:  Front Neurosci       Date:  2018-03-14       Impact factor: 4.677

Review 6.  Convergent pathways in Parkinson's disease.

Authors:  Marta Cherubini; Richard Wade-Martins
Journal:  Cell Tissue Res       Date:  2017-10-23       Impact factor: 5.249

7.  α-Synuclein Translocates to the Nucleus to Activate Retinoic-Acid-Dependent Gene Transcription.

Authors:  Dana Davidi; Meir Schechter; Suaad Abd Elhadi; Adar Matatov; Lubov Nathanson; Ronit Sharon
Journal:  iScience       Date:  2020-02-14

Review 8.  Pathophysiological Mechanisms of Antipsychotic-Induced Parkinsonism.

Authors:  Elena E Vaiman; Natalia A Shnayder; Aiperi K Khasanova; Anna I Strelnik; Arseny J Gayduk; Mustafa Al-Zamil; Margarita R Sapronova; Natalia G Zhukova; Daria A Smirnova; Regina F Nasyrova
Journal:  Biomedicines       Date:  2022-08-18

9.  Calcium CaV1 channel subtype mRNA expression in Parkinson's disease examined by in situ hybridization.

Authors:  Michael J Hurley; Steve M Gentleman; David T Dexter
Journal:  J Mol Neurosci       Date:  2014-08-31       Impact factor: 3.444

10.  Concordant signaling pathways produced by pesticide exposure in mice correspond to pathways identified in human Parkinson's disease.

Authors:  Seema Gollamudi; Ashu Johri; Noel Y Calingasan; Lichuan Yang; Olivier Elemento; M Flint Beal
Journal:  PLoS One       Date:  2012-05-01       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.